Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema

Phase 2 Unknown 53 enrolled University of Sao Paulo Fundação de Amparo à Pesquisa do Estado de São Paulo · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular edema.

Timeline

Start: 2010-04
Primary completion: 2012-09
Completion: 2012-09

Publications

Nepomuceno AB, Takaki E, Paes de Almeida FP, Peroni R, Cardillo JA, Siqueira RC, Scott IU, Messias A, Jorge R. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Am J Ophthalmol. 2013 Sep;156(3):502-510.e2. doi: 10.1016/j.ajo.2013.04.026. Epub 2013 Jun 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	1.5 mg	Other
Subject	Ranibizumab	Monoclonal antibody	0.5 mg	Other

Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema

Summary

Timeline

Publications

Drugs

Indications